NCT01701999已完成2 期
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 4
- 主要终点
- Four-Fold Increase in Neutralizing Antibody Concentration (NAC)
研究概览
简要总结
Study rBV A/B-CL-001 is a Phase 2b, 2-part, open-label, uncontrolled study to evaluate safety, tolerability, and immunogenicity of a single dose of recombinant botulinum vaccine A/B (rBV A/B) for the production of BabyBIG in volunteers previously immunized with the pentavalent botulinum (PBT) toxoid. This study is designed to determine neutralizing antibody levels for botulinum toxin types A and B in healthy subjects who were previously immunized with the PBT for occupational protection and who receive the rBV A/B. Subjects with titers of the neutralizing antibodies against the toxins would be candidates for plasma donation for BabyBIG production.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The volunteer has received pentavalent botulinum toxoid for occupational protection under BB IND 0161, with the previous pentavalent botulinum toxoid dose at least 6 months prior to the planned rBV A/B dose.
- •The volunteer is between the ages of 18 and 69 years at the time of consent.
- •The volunteer is healthy and has an acceptable medical history.
- •The volunteer meets the subject suitability requirements and recommendations for source plasma donors (for Part 2 subjects only).
- •The volunteer, if female and of childbearing potential, is not pregnant or lactating, and agrees to use an acceptable form of FDA-approved contraception for the duration of the study.
- •The volunteer has the ability to understand the requirements of the study and provide informed consent.
- •The volunteer agrees to complete the subject diary on a daily basis for 7 days post-vaccination and to report concomitant medication and adverse events during the study period.
- •The volunteer provides written authorization for use and disclosure of protected health information.
- •The volunteer agrees not to donate blood or blood products (outside of study procedures) during the course of the study.
- •The volunteer has personal health insurance.
排除标准
- •Be pregnant or nursing
- •The volunteer has a history of laboratory evidence of syphilis, acquired immunodeficiency syndrome, Creutzfeldt-Jakob disease, or infection with human immunodeficiency viruses 1 or 2, human T cell lymphotropic virus 1, hepatitis B virus, or hepatitis C virus.
- •The volunteer had prior severe local or severe systemic reaction to last immunization with pentavalent botulinum toxoid.
- •The volunteer has a known allergy to aluminum compounds, yeast, or other components of the vaccine.
- •The volunteer has donated one or more units of blood or undergone plasmapheresis within 28 days before screening.
- •The volunteer has received a blood product or immunoglobulin within 6 months of screening or plans to receive such products during the study.
- •The volunteer has received licensed nonliving vaccine within 14 days before study entry or licensed live vaccine within 60 days before study entry.
- •The volunteer has received investigational products (drugs, biologics, vaccines, or implantable devices) 60 days prior to study entry or plans to receive experimental products at any time during the study.
- •The volunteer has received prescription immunosuppressive or immunomodulatory agents, including parenteral, inhaled, or oral corticosteroids within 3 months before screening or plans on receiving such therapy at any time during the study with the exceptions (Subjects who have used prescription topical steroids may be enrolled 2 weeks after the therapy is completed; Intra-articular, bursal, or tendon injectable steroids are permitted; Any over-the-counter topical steroid use is permitted; Ophthalmic and intranasal steroids are permitted).
- •The volunteer has received cytotoxic therapy at any time in the previous 5 years to study entry.
- •The volunteer has an active systemic or recurrent disease that would place the subject at unacceptable risk of injury, require hospitalization, or require surgical intervention.
- •The volunteer has a history of alcohol or drug abuse within 12 months before screening.
- •The volunteer has past, present, or suspected illicit injection drug use.
- •The volunteer has inflammatory, vasculitic, or rheumatic disease, including systemic lupus erythematosus, polymyalgia rheumatica, rheumatoid arthritis, or scleroderma.
- •The volunteer has clinically recognized hepatic or renal insufficiency.
- •The volunteer has uncontrolled hypertension.
- •The volunteer has moderate to severe asthma, chronic obstructive pulmonary disease, or other significant pulmonary disease.
- •The volunteer has a seizure disorder.
- •The volunteer has moderate or severe illness or oral temperature of 100.4°F or greater within 3 days prior to immunization.
- •The volunteer is determined by the investigator to be unsuitable for participation in this trial for any reason.
结局指标
主要结局
Four-Fold Increase in Neutralizing Antibody Concentration (NAC)
时间窗: Week 0 to Week 4
Proportion of participants achieving a four-fold or greater increase in NAC up to Week 4 compared with Week 0 for both botulinum toxin A and toxin B (a proportion ≥ 0.50 was considered a success).
次要结局
- Three-Fold Increase in Neutralizing Antibody Concentration (NAC)(Week 0 to Week 4)
- Two-Fold Increase in the Area Under the Neutralizing Antibody Concentration (NAC) Curve(Week 0 to Week 12)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.Viral DiseaseNCT04535167Pfizer26
已完成
2 期
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 DiseaseBatten DiseaseJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseCLN2 DisorderNCT02678689BioMarin Pharmaceutical14
招募中
1 期
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaMyelofibrosis Due to and Following Polycythemia VeraPost-essential Thrombocythemia MyelofibrosisMyelodysplastic SyndromesAnemia MyelofibrosisMyelofibrosisPrimary MyelofibrosisAnemiaNCT05320198Disc Medicine, Inc150
终止
1 期
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaNCT04956042CicloMed LLC18
已完成
1 期
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric CancerMetastatic Colorectal CancerGastroesophageal Junction AdenocarcinomaGastric CancerNCT03724851MedPacto, Inc.120